No me preocupa en exceso la cotización a corto plazo...
para mi es un Si claro
en la pagina 14:_
Benefit-Risk Summary The totality of the data across the clinical development program for NVX-CoV2373 demonstrates that it is a highly effective vaccine with an acceptable safety profile for prevention of COVID-19 caused by SARS-CoV-2 infection. NVX-CoV2373 uses a well-established vaccine technology platform, including a recombinant spike protein antigen with a saponin adjuvant derived from a natural product. In addition, NVXCoV2373 offers a reassuring safety profile and favorable reactogenicity profile. NVX-CoV2373 may provide an important option to increase vaccine uptake, including in populations reluctant to utilize newer technologies, and thereby diminish the severe disease and hospitalizations caused by SARS-CoV-2. Considering the ongoing public health emergency due to SARS-CoV-2 and its emerging variants, the need for additional effective vaccines, and the available efficacy, immunogenicity, and safety data across the NVX-CoV2373 clinical development program, the Sponsor considers that the known and potential benefits of the vaccine outweigh its known and potential risks and warrant consideration for authorization in individuals 18 years of age and older.